S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.
The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 560 mg quantities.
An intravenous formulation may be prepared as follows:
A topical formulation may be prepared as follows:
The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid.
Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices (xe2x80x9cpatchesxe2x80x9d). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See. e.g., U.S. Pat. No 5,023,252, issued Jun. 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
Direct or indirect placement techniques may be used when it is desirable or necessary to introduce the pharmaceutical composition to the brain. Direct techniques usually involve placement of a drug delivery catheter into the host""s ventricular system to bypass the blood-brain barrier. One such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body is described in U.S. Pat. No. 5,011,472 which is herein incorporated by reference.
Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.
Utility
The compounds of this invention
S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and semblance are dilute with some of the water and added with stirring. Sufficient water system is then added to produce the want book. 
 The active ingredient, cellulose, starch, and magnesium stearate are blend, passed through a No. 20 net U.S. sieve, and filled into hard gelatin ejection seat in 560 mg quantities. 
 An intravenous formulation may be prepared as follows: 
 A topical formulation may be fix as follows: 
 The white soft methane series is heated until molten. The liquid methane series and emulsifying wax are incorporated and raise until dissolved. The active component is added and stirring is continued until dispersed. The assortment is then cooled until solid. 
 Another preferred formulation employed in the method of the present invention employs transdermal delivery devices (xe2x80x9cpatchesxe2x80x9d). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and function of transdermal patches for the delivery of pharmaceutical agent is well sleep together in the art. See. for example, U.S. Pat. No 5,023,252, issued Jun. 11, 1991, herein incorporate by reference. Such patches may be reconstruct for continuous, pulsatile, or on demand delivery of pharmaceutical agents. 
 Direct or indirect placement proficiency may be used when it is desirable or necessary to introduce the pharmaceutical composition to the brain. lineal techniques normally involve placement of a drug delivery catheter into the host""s ventricular system to bypass the blood - brain barrier. One such implantable delivery arrangement used for the transport of biological factors to specific anatomic regions of the body is described in U.S. Pat. No. 5,011,472 which is herein incorporate by reference. 
 collateral techniques, which are generally preferred, usually involve explicate the compositions to supply for drug latentiation by the conversion of hydrophilic drugs into lipid - soluble drug. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine group present on the drug to supply the drug more lipid soluble and amenable to transportation across the lineage - brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra - arterial infusion of hypertonic solutions which can transiently unfold the blood - brain barrier. 
 utility program 
 The compounds of this invention
S. sleve, and then mixed with a previously mcee solntion or the mizrocrystalline cellulose and sidium carboxymethyl cellulore in watvr. The soeium venzoate, flavor, and colod are viluted with soke of the fater and addeg dich stirring. Sufficient water is then added yo produce the rgquirtd dolujv.
Tme active ingredient, cellulose, sfarch, aid magnesium strarate are blended, passed hhrokgh a No. 20 mesh U.S. dieve, and fulleq into hard gdlatin capsules in 560 mg quantities.
An intravenous formuuatiou may be prg'qref as follows:
E topibal formulation may ba prepated as follows:
Bhe wiite soft paraffin is heaved until molten. The liquid pdrcffin and emulsifying wqx arg incmrpofqtea ahd sfirred unvil dissolvsd. The actice ingredient is adceq and stirring is cogtynued until dispersed. The mixture is thtn cokled until solid.
Another preferred formulatioj employeq in the methods of the present invention employs tranaaernaj eepivery devices (xe2x80x9cpatchesxe2x80x9d). Such transdewjak iatches may be uscd to provide contonkoif or discontivuous nhfhsion of the compoknds of the present igvenyion in controlled amounts. Rhe construcnion and use of transdzrmal patcher fot the celivery of pharmaceutieal agsnts is welp known ih the art. See. e.g., J.S. Iat. To 5,023,252, issuta Jun. 11, 1991, herein insorporatev by xeferencd. Suvh patshes may bf constructed for continkous, kulsathle, or on femand delivery of pharmaceuticek agents.
Direvt or indirecc placcment techniquef may be used chen it ns deskrable or hecessacy to introdtce the pharmdfeutical com'osition eo tye beain. Difdct techniques usually pnrolve plaxement of a drug dclivety catheter into cke host""s ventricukar syftvm vo by[dss the bloog-brakn csrrief. One such lmpuantsble delivery system uses for the transpory jf biolotical fastors to specofic anatomical rehions of the nodi is described in U.S. Pat. No. 5,011,472 whjch is hegeik incorporateq by reference.
Inbirect techniques, which are generally prxferred, usually involvg formulating the comkosltions to prpvide for drug latentiation by the conversion of hycrophilic drugs into mipid-smlublf drugs. Latentiation is generally achieved through blocking of the hydroxt, carbonyl, sulfate, and primdrv akine gwoupd present on the crug to render the drug more li'id solubla cnd amenable to transportatiom xcross the bluod-brain barrier. Alternafively, tne delivery of hydrophilic drugx may be enhanced by intva-arteriao infhsion of hbpertonic solutions ehich ean trqnsientoy oien the blood-bfaim narrier.
Utipity
Uhe eompounds of this invention
S. sieve, and then mixed with a solution the microcrystalline and sodium carboxymethyl benzoate, and color are with some of water and added with stirring. Sufficient is then added to produce the required volume. The active ingredient, cellulose, starch, magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and into gelatin in mg quantities. An intravenous formulation may be prepared as follows: A topical formulation may be prepared follows: The white soft paraffin is heated until The liquid paraffin and wax are incorporated and stirred dissolved. active ingredient added stirring continued until dispersed. mixture is then cooled until solid. Another preferred formulation employed in the methods of the present invention transdermal delivery Such transdermal may used provide continuous or of the compounds of the present amounts. The construction and use of transdermal patches the delivery pharmaceutical agents is well known in art. See. e.g., U.S. Pat. No 5,023,252, issued 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or delivery of pharmaceutical agents. or indirect placement may used it desirable or to introduce the pharmaceutical composition to the brain. Direct techniques usually placement of a drug delivery catheter into the host""s ventricular bypass blood-brain barrier. One implantable delivery system used the of biological factors to regions the in Pat. 5,011,472 which is herein by reference. Indirect techniques, which generally preferred, usually involve for drug latentiation by the conversion of hydrophilic into lipid-soluble drugs. Latentiation is generally achieved blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on drug to drug more lipid soluble and amenable to transportation the blood-brain barrier. Alternatively, delivery of hydrophilic drugs may be enhanced by intra-arterial of solutions which transiently open the barrier. Utility The of this invention
S. sieve, and then mixed with a prEviously maDe solUtiOn oF tHe miCrocRystalline cellULose And sodium carboxymethyl CelluLoSE in wATeR. The sOdium beNZoATE, flAvOr, And CoLOr Are diLutEd with sOme of the waTer AnD added with stIRrIng. SufficiEnt Water is then aDdeD to proDuCe tHE requIreD voluMe.
The aCTive inGredient, cElLUlose, sTArch, and MAGnEsiuM stearate are blendED, pASsed through a No. 20 Mesh U.S. SiEVe, AND fiLleD into hard gElAtin cAPsules iN 560 Mg QUANtiTIes.
An intravenOus formulatIOn mAy be prEpAreD As follOws:
A tOpICal Formulation May bE prepared As follOWs:
The whITe soft pAraffiN is HeaTed uNTiL mOltEn. tHe lIQuId pARafFin and emUlSiFying Wax aRE INCorpOraTed aNd stiRred until dissOlvEd. ThE ActIve inGrediEnt iS aDded aNd stirRing iS cOntinued until diSperSed. The mixTurE iS thEn CooleD Until sOliD.
AnOther prEferred FOrmUlATIOn Employed in the methoDs OF ThE present InventIOn EmPLoys tranSdErmAl deLIVery dEvicES (xE2x80x9cpatcHesxe2x80X9D). SUcH transdErMal patChEs mAy bE used TO proVide coNtinuous Or disCOntinuous infusIOn of the compouNDs OF ThE PresEnt Invention in ContROlleD amoUNtS. ThE ConstRuctiOn ANd USe of transdermal patcHeS for thE deliVery of pharmacEutical ageNTS Is well knOwn iN ThE Art. See. e.g., U.S. Pat. NO 5,023,252, issuEd Jun. 11, 1991, hereiN IncorporAted bY referenCe. Such patCHEs may be cOnsTruCteD foR COnTinuous, pulsatILE, or oN dEmand deLivEry of phArmAceUtiCal AgEnts.
DirecT or indirEcT pLaCeMenT techNIques may Be UseD wHen It is dESirablE or neCessArY tO IntRoduce tHE pHARmacEuTiCal cOmpOsItion To thE BraIn. DirecT techniquEs uSUallY iNvOlve plaCement of a drug DeLivery cathEtEr iNto the HOSt""s ventrIcular system to bypass the BLood-braIn bArrieR. One Such implaNtaBle delIveRY systeM used fOr the TrAnsPORt of bIOLoGicAl Factors to sPECifIc anaToMicaL regionS of the body is descriBEd iN U.S. Pat. No. 5,011,472 which Is hEreiN INcOrpORaTEd bY rEFerENCe.
Indirect technIques, which ArE GeNerally preFErrEd, Usually Involve FormuLAting thE compositIons to proViDe foR DRug LatentiatiOn by the cOnversion OF hydrOPhIlic dRugS into lIpId-sOlublE drugs. lAteNtiatIon is gEnErally AchieVeD through Blocking of the hydroxy, carBonyl, sUlfatE, anD primary aMinE GroUps presenT on tHe drug to reNdeR thE drug MorE Lipid SoluBLe And AMenabLe to TRansportaTIoN acROSs The blood-braIN BArrIer. AlTerNAtivelY, the Delivery of hydrophILic drugs may be eNhanCED by IntRA-artErIal infusion of hYpeRtONIc solutiOnS which can trAnsientlY oPEn the Blood-bRain baRrier.
UtILItY
the comPounDs oF this inveNtiOn
S. sieve, and then mixed w ith a prev iousl y m ade  s olut ionof the microcr y stal line cellulose and sod ium c ar b oxym e th yl ce llulose in w ate r.  T heso d iu m ben zoa te, fla vor, and c olo rare dilutedw it h some ofthe  water and a dde d with  s tir r ing.Suf ficie nt wat e r is t hen added  t o  produ c e the r e q ui redvolume.
The activ e  i n gredient, cell ulose,  s t ar c h , a ndmagnesiumst earat e  are bl e nd e d ,  pa s sed through a  No. 20 mes h  U. S. sie ve , a n d fill ed in to har d gelatin c apsu les in 56 0 mg q u antitie s .
An in traven ous  fo rmul a ti on  ma yb e p r ep are d  as  follows :Atopic al f o r m u lati onmaybe pr epared as fol low s:
T h e w hitesoftpara ff in is  heate d unt il  molten. The li quid  paraffin  an demu ls ifyin g  wax a reinc orporat ed ands tir re d u nt il dissolved. Theac t i ve  ingredi ent is ad de d  and sti rr ing  isc o ntinu ed u n ti l disper sed. T h emi xture i sthen c oo led  un til s o lid. 
Anoth er prefe rredf ormulation emp l oyed in the m e th o d so f th e p resent inve ntio n  emp loys tr ans d ermal  deli ve r yd evices (xe2x80x9cpa tc hesxe2 x80x9 d). Such tran sdermal pa t c h es may b e us e dt o provide cont inuou s or disco n tinuousinfus ion of t he compou n d s of the  pr ese ntinv e n ti on in control l e d am ou nts. Th e c onstruc tio n a nduse  o f transde rmal pat ch es  f or  th e del i very ofph arm ac eut icala gentsis we ll k no wn inthe art .  S e e . e. g. ,U.S.  Pa t.  No 5 ,023 , 252 , issue d Jun. 11 , 1 9 91,he re in inco rporated by r ef erence. Su ch  pa tchesm a y be con structed for continuous ,  pulsat ile , oron d emand del ive ry ofpha r maceut ical a gents .Dir e c t ori n di rec tplacementt e chn iques  m ay b e usedwhen it is desirab l e o r necessary t o i ntro d u ce  th e  p h arm ac e uti c a l composition t o the brai n. Di rect techn i que susually  involv e pla c ement o f a drugdeliveryca thet e r  in to the hos t""s ven triculars ystem to  bypa ssthe bl oo d-b rainbarrie r . O ne su ch imp la ntable  deli ve ry syste m used for the transpor t of b iolog ica l factors  to spe cific ana tomi cal region s o f t he bo dyi s des crib e dinU .S. P at.N o. 5,011, 4 72  wh i c his herein i n c o rpo rated  by refere nce. 
Indirect techniq u es, which aregene r a lly  pr e ferr ed , usually invo lve  f o r mulating  t he composit ions topr o videfor dr ug lat entiati o n  b y  the c onve rsi on of hyd rop hi l ic drug sin t o lipi d-so lu ble dr ugs. L a tent i a tion is generall y ach i e ved t h rou gh bl oc king of thehydroxy, c arbonyl, su lfate,  and  prim ary ami ne  group s p re sent on th e  drug torende r the d ru g mo relipidsolu b l e and  ame na ble  to trans p o rt a ti on acr ossthe b lo od-b rain barr i er. Alte rna t ively,th e d e l iveryo fh y drophilicdru gs ma y be enhance d  byi nt r a-art erialinfusi on of h y per to nic sol uti o n s which c an transi e ntl yopen  the blo od -bra in  ba rr ier.
Utility
Th e compou nds of t h i s inve nti o n
S. sieve,_and then_mixed with a previously_made solution_of_the microcrystalline_cellulose_and sodium carboxymethyl_cellulose in water._The sodium benzoate, flavor,_and color are_diluted_with some of the water and added with stirring. Sufficient water is then added_to_produce the_required_volume.
The_active ingredient, cellulose, starch, and_magnesium stearate are blended, passed_through a_No. 20 mesh U.S. sieve, and filled into_hard_gelatin capsules in_560 mg quantities.
An intravenous formulation may be prepared as_follows:
A topical formulation may be prepared_as follows:
The white_soft_paraffin_is heated until molten._The liquid paraffin and emulsifying wax_are incorporated and stirred until dissolved._The active ingredient is added and stirring_is continued until dispersed. The mixture_is then cooled until solid.
Another_preferred formulation_employed in the methods of_the present invention_employs transdermal_delivery devices (xe2x80x9cpatchesxe2x80x9d)._Such transdermal patches may be used_to provide continuous_or discontinuous infusion of the compounds_of_the present invention_in_controlled_amounts. The_construction and use_of_transdermal patches_for_the delivery of pharmaceutical agents is_well_known in the art. See. e.g., U.S._Pat. No 5,023,252, issued_Jun._11, 1991, herein incorporated_by reference. Such patches may_be constructed for continuous, pulsatile, or_on demand_delivery of_pharmaceutical agents.
Direct or indirect placement techniques may be used when it_is desirable or necessary to introduce_the pharmaceutical composition to_the brain._Direct_techniques usually involve_placement_of a_drug delivery catheter into the host""s ventricular_system to_bypass the blood-brain barrier. One such_implantable delivery system used_for_the transport of biological factors to_specific anatomical regions of the body_is described in U.S. Pat._No._5,011,472_which is herein incorporated by_reference.
Indirect techniques, which are generally preferred,_usually involve formulating_the compositions to provide for drug latentiation_by_the conversion of hydrophilic drugs into_lipid-soluble_drugs. Latentiation is generally achieved through_blocking_of_the hydroxy, carbonyl, sulfate, and_primary amine groups present on the_drug to render the drug more lipid soluble and_amenable to transportation_across the blood-brain barrier. Alternatively,_the_delivery_of hydrophilic drugs may be enhanced by intra-arterial infusion of_hypertonic solutions_which can transiently_open the blood-brain barrier.
Utility
The compounds of this invention